No profile data available.
Nuvation Bio Inc. (NUVB) is a healthcare company in the additional cancer treatment drugs industry, based in New York, United States, with about 305 full-time employees.
It reported revenue of $62.90 million for fiscal year 2025, up 699.0% from fiscal year 2024, and net income of -$204.63 million. Japan was its largest region in fiscal year 2025, with 46% of revenue. Its market capitalization was $1.76 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
Nuvation Bio reported $62.90 million in revenue for fiscal year 2025, up 699.0% from $7.87 million in fiscal year 2024.
Japan: 46% of revenue by region in fiscal year 2025, followed by United States (39%).
$1.76 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Immunome, Inc. (IMNM), Zymeworks Inc. (ZYME), UroGen Pharma Ltd. (URGN), Inhibrx Biosciences, Inc. (INBX).